Development of a penem antibiotic against Mycobacteroides abscessus

Hunter R. Batchelder, Elizabeth Story-Roller, Evan P. Lloyd, Amit Kaushik, Kristina M. Bigelow, Emily C. Maggioncalda, Eric L. Nuermberger, Gyanu Lamichhane, Craig A. Townsend

Research output: Contribution to journalArticlepeer-review


β-lactams are the most widely used antibiotic class to treat bacterial infections in humans. Mycobacteroides abscessus is an emerging pulmonary pathogen resistant to most antibiotics, including penicillins and cephalosporins. With no current FDA-approved treatment and cure rates <50%, there is a pressing need for effective therapies. Here we report T405, a new β-lactam of the penem subclass that exhibits potent activity against M. abscessus and a panel of drug-resistant strains isolated from cystic fibrosis patients. Additionally, in combination with the β-lactamase inhibitor avibactam, the rate of spontaneous resistance of M. abscessus to T405 approached the limit of detection. Lastly, we show the favorable pharmacokinetic profile of T405 in mice and the absence of toxicity at elevated dosage, which support the clinical potential of this compound.

Original languageEnglish (US)
Article number741
JournalCommunications biology
Issue number1
StatePublished - Dec 2020

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • General Biochemistry, Genetics and Molecular Biology
  • General Agricultural and Biological Sciences


Dive into the research topics of 'Development of a penem antibiotic against Mycobacteroides abscessus'. Together they form a unique fingerprint.

Cite this